Assessing whether ARS Pharmaceuticals (trading under ticker ABOS) is an attractive investment involves examining its commercialization progress, regulatory approvals for core allergy treatments like nasal sprays, and overall cash runway. Investors should review current clinical milestone data, institutional ownership metrics, and competitive market positioning against alternative pharmaceutical treatments before deciding to add shares to a portfolio.